This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Authoring team

  • key features of SFTS are high fever and a low platelet count

  • illness begins with a non-specific, viraemic prodrome, which is often flu-like and associated with fever
    • gastrointestinal disturbances may also be present, including abdominal pain, vomiting and diarrhoea
    • prodrome lasts for around 7 days
    • incubation period is 7 to 14 days, typically around 9 days

  • appears to be a spectrum of disease, with some patients only having a mild illness, which resolves spontaneously.In those who have progressive disease, severe illness typically develops in the second week
    • in those who survive severe illness, signs of recovery usually emerge around days 8 to 11 of illness, accompanied by a decrease in blood viral load and recovery of the platelet count
    • in fatal cases, high-level viraemia and thrombocytopaenia persist or worsen; often associated with increasing blood levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

  • reported complications include acute kidney injury, myocarditis, haemorrhage (including disseminated intravascular haemorrhage), meningioencephalitis, haemophagocytic lymphohistiocytosis, and multi-organ dysfunction

Reference:

  • Public Health England (April 2021). Severe fever with thrombocytopaenia syndrome (SFTS): epidemiology, outbreaks and guidance

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.